Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
This article was originally published in PharmAsia News
Executive Summary
Novartis is concerned that the changing intricacies of the Indian legal system will indefinitely delay its court case challenging the Indian Patent Office's denial of the Gleevec (imatinib) patent in the developing country